You don’t let the fuel crew decide the flight path. You don’t let finance set the altitude. And you don’t fly without instruments.
Medication Procurement Is Like Flying a Plane
Medication procurement is no different. It demands precision, separation of duties, and a cockpit with real-time visibility. When treated as a simple cost function, systems crash into preventable shortages, therapeutic failures, and compliance breaches. But when governed as an integrated clinical function, supported by operations and finance, it becomes a strategic capability that ensures safe passage for every patient.
1. The Flight Plan (Operational Strategy)
This is the actionable “how.” It involves formulary-driven purchasing, strategic sourcing using the Most Economically Advantageous Tender (MEAT) principle (not just the lowest bid), and managing the total cost: acquisition price, inventory holding, operational overhead, and the hidden cost of shortages.
2. The Co-Pilot’s Authority (Clinical Safety)
The Pharmacy Department is the non-negotiable clinical authority. This isn’t a suggestion; it’s codified by global bodies from WHO and NHS England to ASHP and EAHP. Pharmacy owns the formulary, verifies therapeutic and bioequivalence (via the FDA Orange Book), and bio-similarity for biological products (via the FDA Purple Book),enforces strict protocols for Narrow Therapeutic Index (NTI) drugs, and ensures patient usability. No purchase order takes off without this clearance.
3. The Cockpit Crew (Governance Structure)
Each role has a separate, vital control:
- Pharmacy (Clinical Co-Pilot): Authorizes what enters the system.
- Procurement (Flight Operations): Executes how to source it, including tendering, contracts, and logistics, all within approved parameters.
- Finance (Flight Logistics): Manages the budget and fuel, ensuring fiscal control without touching the clinical or operational controls.
This separation isn't bureaucracy. It's the structural integrity that prevents a single point of failure.
4. Post-Flight Diagnostics (The Validation Loop)
Governance doesn’t end at delivery. For high-risk cargo, such as generics, biosimilars, and NTI drugs, active pharmacovigilance is mandatory. Monitoring adverse reactions and therapeutic outcomes is the essential feedback loop that validates the initial procurement decision and informs future sourcing.
The Autopilot (Automation as the Governance Engine)
Scaling this model manually is impossible. Intelligent automation is the force multiplier:
- Automates clinical evaluation workflows and compliance checks.
- Predicts demand and triggers smart replenishment.
- Guarantees end-to-end traceability from manufacturer to to the patient, whether at the bedside or in the home, via systems like GS1, Tatmeen, or SFDA Track and Trace.
- Provides the real-time dashboard and cockpit instruments for full visibility.
The Control Panel: Knowing Your Governance Altitude
The Medication Procurement Governance Maturity Model provides that instrument panel, defining a progression from reactive to predictive control. This concept of benchmarking maturity is supported by global methodologies used to assess system capability.
- Level 1 (Initial): Ad-hoc, undocumented. The engine is running, but there’s no flight plan.
- Level 2 (Developing): Basic procedures exist but are inconsistent. Flying visually with occasional instrument checks.
- Level 3 (Defined): Formal policies and digital tools are in place. Flying with a map and a co-pilot.
- Level 4 (Managed): Performance is measured and managed with data. The autopilot is engaged for core functions.
- Level 5 (Optimized): Fully integrated, predictive, and continuously improving. The entire flight is proactively managed by an integrated system.
Real-world systems publicly demonstrate traits across this spectrum. For instance, highly centralized systems, such as those with national procurement bodies, can achieve strong consistency and leverage, aligning with Level 4 to Level 5 characteristics. Conversely, decentralized or fragmented systems often exhibit strengths in institutional flexibility but face challenges in national coordination, standardization, and shortage mitigation, traits that align with a Level 3 maturity environment.
The model’s power is not in publicly ranking others, but in providing an honest internal diagnostic. Where would your organization plot itself? Are you reacting to shortages, or predicting them? Is every substitution clinically justified and traceable, or are there blind spots?
Progress is often hindered by the very gaps the model reveals: siloed governance, underinvestment in automation, and the critical disconnect between clinical authority and procurement workflow. Treating this not as a one-time checklist, but as a living strategic standard, is what allows systems to navigate toward safety, reliability, and true efficiency.
From Framework to Impact
This framework is not theoretical. It is the operational standard of the world’s most resilient health systems. It transforms procurement from a cost center into a clinical safeguard and strategic asset.
The question for leadership is no longer if but how fast you can mature your governance model. The cost of inaction is measured in preventable patient harm, financial leakage, and operational instability.
It's time to align your crew, engage the autopilot, and ensure every procurement decision navigates safely to its only important destination: patient outcomes.
Reference List
- World Health Organization. (1999). Operational principles for good pharmaceutical procurement. Geneva: WHO.
- American Society of Health-System Pharmacists. (2012). Minimum standard for pharmacies in hospitals. https://www.ashp.org
- European Association of Hospital Pharmacists. (2019). Position paper on procurement. European Journal of Hospital Pharmacy, 26(3), 173–174.
- Medication Procurement Governance Excellence Framework. (n.d.). Internal institutional U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book
- U.S. Food and Drug Administration. (n.d.). Purple Book database of licensed biological products. https://purplebooksearch.fda.gov/
- NHS England. (n.d.). Medicines procurement and supply chain framework. https://www.england.nhs.uk/medicines-2/medicines-value-and-access/medicines-procurement-and-supply-chain/
- Management Sciences for Health. (2012). Managing drug supply (2nd ed., Chapter 18). Kumarian Press.
- Saudi Food and Drug Authority. (n.d.). Pharmaceutical track and trace system (RSD). https://rsd.sfda.gov.sa/index-en.html
- UAE Ministry of Health and Prevention. (2021). Tatmeen: National pharmaceutical serialization and traceability platform. https://www.mohap.gov.ae/en/services/tatmeen
- European Parliament and Council. (2014). Directive 2014/24/EU on public procurement. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32014L0024
- Organization for Economic Co-operation and Development. (2025). Implementing the OECD recommendation on public procurement. https://www.oecd.org/governance/public-procurement/
- International Pharmaceutical Federation. (2012). FIP statement of policy: The role of the pharmacist in the selection and use of medicines. https://www.fip.org/file/1503
- European Medicines Agency, & Heads of Medicines Agencies. (2022). Questions and answers on biosimilar medicines (revision 1). https://www.ema.europa.eu/en/documents/leaflet/questions-answers-biosimilar-medicines-revision-1_en.pdf
- Council for International Organizations of Medical Sciences (CIOMS). (2020). CIOMS guide to active vaccine safety surveillance: Report of CIOMS working group. https://cioms.ch/publications/product/cioms-guide-to-active-vaccine-safety-surveillance/
- Vogler, S., & Habimana, K. (2022). Medicines procurement in Europe: An overview of policies, approaches, and practices. European Commission. https://health.ec.europa.eu/publications/medicines-procurement-europe-overview-policies-approaches-and-practices_en
- GS1. (2021). GS1 Healthcare reference book: Improving patient safety through traceability. https://www.gs1.org/docs/healthcare/GS1_Healthcare_Reference_Book.pdf
- World Health Organization. (2021). Global Benchmarking Tool (GBT) for evaluation of national regulatory systems.
